Assessment of the feed additive consisting of alpha‐galactosidase produced by Saccharomyces cerevisiae CBS 615.94 and endo‐1,4‐beta‐glucanase produced by Aspergillus niger CBS 120604 (Agal‐Pro BL/BL‐L®) for use in chickens for fattening, minor poultry species for fattening and chickens reared for laying for the renewal of its authorisation (Kerry Ingredients & Flavours Ltd.)
Meta data
Legal notice: Relevant information or parts of this scientific output have been blackened in accordance with the confidentiality requests formulated by the applicant pending a decision thereon by the European Commission. The full output has been shared with the European Commission, EU Member States and the applicant. The blackening will be subject to review once the decision on the confidentiality requests is adopted by the European Commission.
Abstract
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application for renewal of Agal‐Pro BL/BL‐L®. The additive is a preparation of alpha‐galactosidase produced by a genetically modified strain of Saccharomyces cerevisiae (CBS 615.94) and endo‐1,4‐beta‐glucanase produced by a non‐genetically modified strain of Aspergillus niger (CBS 120604). It is intended to be used as a zootechnical additive (functional group: digestibility enhancers) in chickens for fattening in its solid and liquid forms (Agal‐Pro BL® and Agal‐Pro BL‐L®), and in minor poultry species for fattening and chickens reared for laying only in its solid form (Agal‐Pro BL®). The applicant has provided evidence that the additive currently on the market complies with the existing conditions of authorisation. There is no new evidence that would lead the FEEDAP Panel to reconsider its previous conclusions. Thus, the Panel concludes that the additive remains safe for the target animals, consumers and the environment under the authorised conditions of use. Regarding user safety, the additive is considered an irritant to the skin and eyes and a dermal sensitiser. Due to the proteinaceous nature of the active substances, it should be considered a respiratory sensitiser. There is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.